Q3 2025 13F Holders as of 30 Sep 2025
-
Type / Class
-
Equity / Common Stock
-
Shares outstanding
-
61,152,075
-
Total 13F shares
-
63,798,487
-
Share change
-
+1,080,403
-
Total reported value
-
$12,683,838,954
-
Put/Call ratio
-
29%
-
Price per share
-
$198.81
-
Number of holders
-
279
-
Value change
-
+$232,138,786
-
Number of buys
-
154
-
Number of sells
-
114
Institutional Holders of Ascendis Pharma A/S - Common Stock (ASND) as of Q3 2025
As of 30 Sep 2025,
Ascendis Pharma A/S - Common Stock (ASND) was held by
279 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
63,798,487 shares.
The largest 10 holders included
RA CAPITAL MANAGEMENT, L.P., WESTFIELD CAPITAL MANAGEMENT CO LP, Avoro Capital Advisors LLC, FMR LLC, JANUS HENDERSON GROUP PLC, Artisan Partners Limited Partnership, Capital International Investors, T. Rowe Price Investment Management, Inc., MASSACHUSETTS FINANCIAL SERVICES CO /MA/, and WELLINGTON MANAGEMENT GROUP LLP.
This page lists
279
institutional shareholders reporting positions in this security
for the Q3 2025 filing period.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price
|
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.